These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 34162484)

  • 21. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials.
    Naqash A; Ara R; Bader GN
    BMC Womens Health; 2018 Jan; 18(1):6. PubMed ID: 29304848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency.
    Charles-Edwards G; Amaral N; Sleigh A; Ayis S; Catibog N; McDonagh T; Monaghan M; Amin-Youssef G; Kemp GJ; Shah AM; Okonko DO
    Circulation; 2019 May; 139(21):2386-2398. PubMed ID: 30776909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of an accelerated intravenous iron regimen in hospitalized patients with advanced heart failure and iron deficiency.
    Reed BN; Blair EA; Thudium EM; Waters SB; Sueta CA; Jensen BC; Rodgers JE
    Pharmacotherapy; 2015 Jan; 35(1):64-71. PubMed ID: 25556867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
    Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
    Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.
    Pollock RF; Biggar P
    Expert Rev Hematol; 2020 Feb; 13(2):187-195. PubMed ID: 31928094
    [No Abstract]   [Full Text] [Related]  

  • 26. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial.
    Auerbach M; Henry D; Derman RJ; Achebe MM; Thomsen LL; Glaspy J
    Am J Hematol; 2019 Sep; 94(9):1007-1014. PubMed ID: 31243803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The differential effect of modern intravenous iron on fibroblast growth factor 23 and phosphate in non-dialysis dependent CKD - the exploratory randomized controlled double-blind ExplorIRON-CKD study.
    Kassianides X; Bhandari S
    BMC Nephrol; 2024 Feb; 25(1):54. PubMed ID: 38347520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study.
    Kawabata H; Tamura T; Tamai S; Fujibayashi A; Sugimura M;
    Int J Hematol; 2022 Nov; 116(5):647-658. PubMed ID: 35790696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety of intravenous iron sucrose use in the elderly patient.
    Reed J; Charytan C; Yee J
    Consult Pharm; 2007 Mar; 22(3):230-8. PubMed ID: 17658969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia.
    Ito K; Akizawa T; Arita K; Mitobe Y; Komatsu N
    Clin Exp Nephrol; 2024 Jul; 28(7):636-646. PubMed ID: 38402503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
    Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD;
    BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iron Treatment Strategies in Dialysis-Dependent CKD.
    Pandey R; Daloul R; Coyne DW
    Semin Nephrol; 2016 Mar; 36(2):105-11. PubMed ID: 27236131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia.
    Fishbane S; Block GA; Loram L; Neylan J; Pergola PE; Uhlig K; Chertow GM
    J Am Soc Nephrol; 2017 Jun; 28(6):1851-1858. PubMed ID: 28082519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron Deficiency in Heart Failure: An Overview.
    von Haehling S; Ebner N; Evertz R; Ponikowski P; Anker SD
    JACC Heart Fail; 2019 Jan; 7(1):36-46. PubMed ID: 30553903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease].
    Romanet T; Bedouch P; Zaoui P
    Nephrol Ther; 2019 Apr; 15(2):104-109. PubMed ID: 30803900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ferric carboxymaltose in patients with heart failure and iron deficiency.
    Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
    N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)
.
    Jensen G; Gøransson LG; Fernström A; Furuland H; Christensen JH
    Clin Nephrol; 2019 Apr; 91(4):246-253. PubMed ID: 30614439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Oral Supplementation with Liposomal Iron in Non-Dialysis Chronic Kidney Disease Patients with Iron Deficiency.
    Cesarano D; Borrelli S; Campilongo G; D'Ambra A; Papadia F; Garofalo C; De Marco A; Marzano F; Ruotolo C; Gesualdo L; Cirillo P; Minutolo R
    Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.